OR WAIT 15 SECS
Where is AI delivering the most quantifiable ROI in pharma and biotech today and why are so many pilots failin...
The central government has invited new applications under the Production-Linked Incentive Scheme to promote do...
Google.org has provided $2.3 million in funding, $200,000 in Google Cloud credits, and pro bono technical expe...
INDIA 2030: WHO SUPPLIES THE NEXT 10 MILLION?
India’s diabetes market is entering a defining decade. The withdrawal of selected human insulin pens by Novo Nordisk, the arrival of once-weekly insulin, the rapid expansion of generic semaglutide and the growing adoption of glucose-monitoring technologies are reshaping competition. As pharmaceutical companies and technology providers reposition themselves, the market is splitting into four distinct territories: mass-market insulin, premium insulin, diabetes technology and therapies that may delay insulin initiation. This cover story examines the companies, strategies and innovations shaping the next phase of growth—and asks whether market expansion will translate into better, more affordable diabetes care for millions of Indians.
For Feedback, please email us at: communications@mmactiv.com
